Bellicum Pharmaceuticals has appointed William Grossman, M.D., Ph.D., as chief medical officer, effective February 5. Dr. Grossman joins Bellicum from Genentech/Roche.

“We are excited to have Bill join Bellicum. His expertise in the development of cancer immunotherapies and combinations will strengthen our team as we advance and expand our CAR T and TCR pipeline and prepare for the regulatory filing and potential commercialization of BPX-501 in Europe,” said Bellicum’s president & chief executive officer, Rick Fair.

In his most recent role at Genentech, Dr. Grossman served as the Group Medical Director, Cancer Immunotherapy, where he led the global clinical development of TECENTRIQ in gastrointestinal cancers and of cancer immunotherapy combinations across all solid tumor types. Previously, he served as Senior Vice President, Research & Clinical Development at Biothera, where he oversaw all discovery and clinical development efforts in oncology and immunology. Dr. Grossman has also held leadership positions in research, clinical development, and medical affairs at AbbVie, Baxter Healthcare, and Merck & Co., where he was involved in the development and clinical study of cancer vaccines, immunomodulatory agents, and small molecules/biologics in oncology.